Nkarta Inc Stock Today
| NKTX Stock | USD 2.87 0.12 4.01% |
Performance0 of 100
| Odds Of DistressOver 74
|
Nkarta is trading at 2.87 as of the 30th of November 2024; that is 4.01 percent decrease since the beginning of the trading day. The stock's open price was 2.99. Nkarta has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Nkarta Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of July 2020 | Category Healthcare | Classification Health Care |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Nkarta operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 70.57 M outstanding shares of which 6.77 M shares are now shorted by private and institutional investors with about 7.05 trading days to cover. More on Nkarta Inc
Moving against Nkarta Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Nkarta Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Paul Hastings | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNkarta can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nkarta's financial leverage. It provides some insight into what part of Nkarta's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nkarta Inc (NKTX) is traded on NASDAQ Exchange in USA. It is located in 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 and employs 159 people. Nkarta is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 211 M. Nkarta Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 70.57 M outstanding shares of which 6.77 M shares are now shorted by private and institutional investors with about 7.05 trading days to cover.
Nkarta Inc currently holds about 412.95 M in cash with (86.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Nkarta Probability Of Bankruptcy
Ownership AllocationNkarta Inc maintains a total of 70.57 Million outstanding shares. The majority of Nkarta outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nkarta Inc to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nkarta Inc. Please pay attention to any change in the institutional holdings of Nkarta as this could imply that something significant has changed or is about to change at the company. Also note that almost two million five hundred ninety-six thousand nine hundred thirty-two invesors are currently shorting Nkarta expressing very little confidence in its future performance.
Check Nkarta Ownership Details
Nkarta Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wasatch Advisors Lp | 2024-09-30 | 1.8 M | |
| Ameriprise Financial Inc | 2024-06-30 | 1.2 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.2 M | |
| Alyeska Investment Group, L.p. | 2024-09-30 | 1.1 M | |
| State Street Corp | 2024-06-30 | 1.1 M | |
| Renaissance Technologies Corp | 2024-09-30 | 884.3 K | |
| Orbimed Advisors, Llc | 2024-06-30 | 800 K | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 792.8 K | |
| Superstring Capital Management Lp | 2024-09-30 | 740.3 K | |
| Ra Capital Management, Llc | 2024-09-30 | 10.8 M | |
| Commodore Capital Lp | 2024-09-30 | 4.7 M |
Nkarta Historical Income Statement
Nkarta Stock Against Markets
Nkarta Corporate Management
| Ralph Brandenberger | Chief Officer | Profile | |
| Nadir Mahmood | Chief Officer | Profile | |
| Greg Mann | Vice Relations | Profile | |
| Yvonne MBA | Chief Officer | Profile | |
| Alicia Hager | Chief Secretary | Profile | |
| James Trager | Chief Officer | Profile |
Additional Tools for Nkarta Stock Analysis
When running Nkarta's price analysis, check to measure Nkarta's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nkarta is operating at the current time. Most of Nkarta's value examination focuses on studying past and present price action to predict the probability of Nkarta's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nkarta's price. Additionally, you may evaluate how the addition of Nkarta to your portfolios can decrease your overall portfolio volatility.